VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$25.79-7.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put VKTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskVKTX's Phase 3 obesity trial must succeed to justify the price. Recent positive data supports this clinical development path. The stock hit a 52-week low recently. The company is unprofitable, so no clean multiple exists. Peer multiples imply a price about 69% above where it trades. Our model puts the next-quarter miss near 57%. The thesis is intact, but this read is provisional.
Trailing returns as of 2026-11-05. VKTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering VKTX (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for VKTX in the last 4 months.
Continue this research
Compare VKTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VKTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put VKTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance VK2735 Phase 3 obesity trials
Initiation of pivotal Phase 3 trial confirms key growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $25.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $25.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Fund pipeline development and commercial readiness
Successful capital raise secures funding for pipeline development.
Advances: Advance VK2735 Phase 3 obesity trials
Positive drug data directly supports Phase 3 obesity trial objective.
Advances: Fund pipeline development and commercial readiness
Official confirmation of $575M raise strengthens capital allocation thesis.
Advances: Evaluate VK2735 maintenance dosing strategies
Identifies maintenance dosing as a new growth driver, aligning with objective.
Advances: Advance VK2735 Phase 3 obesity trials
Positive VK2735 results support the core Phase 3 trial objective.
Threatens: Fund pipeline development and commercial readiness
Stock drop on upsized offering signals market concern over dilution.
Advances: Advance Phase 3 clinical development of VK2735 for obesity
Positive trial results support VK2735's development for obesity.
